StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
RNAAtrium Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$8.18▼ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $139.9MShares out 17.1M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

21
  • 10.9Pre-market26.10.09 19:17
    8-K/AKey event#●●●#●●●#●●●

    Atrium Therapeutics, Inc.

    Atrium Therapeutics is conducting a private placement to issue 5,170,384 shares of common stock and pre-funded warrants to purchase up to 1,134,930 shares, as per the agreement dated October 7, 2026. Following this offering, the company's total outstanding shares will be 21,571,507, and this filing serves to correct the previously disclosed share count from the original 8-K.…more

    $8.18-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8Pre-market26.10.08 19:52
    8-KKey event

    Atrium Therapeutics, Inc.

    Atrium Therapeutics has finalized a private placement financing of approximately $50 million with institutional investors. The offering consists of 5,170,384 shares of common stock and pre-funded warrants for 1,134,930 shares, with the proceeds intended to fund product development and operations through 2028.…more

    $8.18-0.12%vs prev close
    View filingShare
  • 9.22After-hours26.09.23 05:24
    4Ownership

    Atrium Therapeutics, Inc.

    Insider Husam Younis of Atrium Therapeutics reported a change in beneficial ownership of securities effective September 18, 2026. This filing is a standard disclosure of insider equity transactions via Form 4.…more

    $8.18-0.12%vs prev close
    View filingShare

20 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 5d agoPre-market26.10.20 21:12
    Bullish#●●●#●●●#●●●

    Yakira Capital Urges Atrium Therapeutics to Explore Strategic Sale

    Shareholder Yakira Capital criticized Atrium Therapeutics for a $50 million dilutive financing following a significant stock price decline. The firm is now calling on the board to immediately explore strategic alternatives, including a potential sale or partnerships, to protect shareholder value.…more

    $8.18-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 10.8Pre-market26.10.08 19:36

    ●●●●●●●● ●●●●● ●●●●●●

    Atrium Therapeutics has entered into a securities purchase agreement for a $50 million private placement with institutional investors. The proceeds will be used to fund the development of its lead product candidates and general corporate operations.…more

    $8.18-0.12%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →